Carrying the torch & facing new challenges Haidong Dong Editorial 03 November 2020 Pages: 2411 - 2412
Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis Haizhu ChenDaquan WangYuankai Shi Review 04 August 2020 Pages: 2413 - 2424
Current trends in cancer immunotherapy: a literature-mining analysis Stamatia PouliliouChristos NikolaidisGeorge Drosatos Original Article 15 June 2020 Pages: 2425 - 2439
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment Yong Joon KimJihei Sara LeeChristopher Seungkyu Lee Original Article 17 June 2020 Pages: 2441 - 2452
Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies Barry D. HockJudith L. McKenzieMargaret J. Currie Original Article 16 June 2020 Pages: 2453 - 2464
Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model Brittany L. BunchKrithika N. KodumudiJoseph Markowitz Original Article 18 June 2020 Pages: 2465 - 2476
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer Naoko KomuraSeiji MabuchiTadashi Kimura Original Article 19 June 2020 Pages: 2477 - 2499
The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice Stefania CuzzubboClaire BanissiAntoine F. Carpentier Original Article 19 June 2020 Pages: 2501 - 2512
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab A. SimonaggioR. ElaidiY. A. Vano Original Article 19 June 2020 Pages: 2513 - 2522
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer Yinli YangLing LiZhanyu Pan Original Article 23 June 2020 Pages: 2523 - 2532
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients Yusuke OmuraYuji ToiyamaMasato Kusunoki Original Article 23 June 2020 Pages: 2533 - 2546
Increased IL-10+CD206+CD14+M2-like macrophages in alveolar lavage fluid of patients with small cell lung cancer Xintong HuYue GuYanfang Jiang Original Article 24 June 2020 Pages: 2547 - 2560
A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities Fenglan WuYangsheng QiuYuhong Xu Original Article 24 June 2020 Pages: 2561 - 2569
TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells Qingming GuoPeng ZhaoLin Hou Original Article 25 June 2020 Pages: 2571 - 2587
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases Yanina JansenVibeke KruseBart Neyns Original Article 26 June 2020 Pages: 2589 - 2598
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer Fan ZhangHua BaiXueda Hu Original Article 26 June 2020 Pages: 2599 - 2611
Multi-antigen DNA vaccine delivered by polyethylenimine and Salmonella enterica in neuroblastoma mouse model Maria V. StegantsevaVeronika A. ShinkevichAlexander N. Meleshko Original Article 27 June 2020 Pages: 2613 - 2622
Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy Jie-ying LiangShao-yan XiYu-hong Li Original Article 29 June 2020 Pages: 2623 - 2634
Characterizing caspase-1 involvement during esophageal disease progression Gillian BarberAkanksha AnandEmma M. Creagh Original Article 01 July 2020 Pages: 2635 - 2649
Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer Yuxin CheYang YangXuelian Wang Original Article 01 July 2020 Pages: 2651 - 2664
Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis Yun-Bin ZhangShi-Jia LiuFan Xia Research Report 06 August 2020 Pages: 2665 - 2671
